Business
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial HypertensionBOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension (“PAH”), today reported financial results for the year ended December 31, 2024 and highlighted recent developments. “The
About this update from Inhibikase Therapeutics, Inc.
[{"type":"image","alt":"Inhibikase Therapeutics","displaySize":"","headline":null,"caption":"Inhibikase Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":136,"url":"https://media.zenfs.com/en/globenewswire.com/130e53897dc7f576187ef1917e07dc52"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Jrx7oJ.q30fX7LRFGfs16Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/130e53897dc7f576187ef1917e07dc52","width":300,"height":136}},"lazy":false},{"type":"text","content":"New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension","length":126,"tagName":"p"},{"type":"text","content":"BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension (“PAH”), today reported financial results for the year ended December 31, 2024 and highlighted recent developments.","length":368,"tagName":"p"},{"type":"text","content":"“The financing concluded in October positioned us to focus our clinical development efforts on advancing IkT-001 toward a late-stage clinical trial in PAH,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “To drive the Company toward its next phase of growth, we subsequently added depth to our management team with the additions of Chris Cabell and John Adams, two accomplished scientific leaders with established track records in the PAH space. Additionally, we expect Chris and John will enable us to accelerate the build out of our team as we make preparations to execute on the IkT-001 Phase 2b clinical trial in PAH. We enter 2025 well positioned to aggressively advanced our IkT-001 development plan.”","length":717,"tagName":"p"},{"type":"text","content":"Recent Developments:","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Closed a private placement with gross proceeds of approximately $110 million in October 2024 in support of advancing IkT-001 into a late-stage clinical trial in PAH. If the warrants issued in such offering are exercised for cash, the aggregate total gross proceeds from the financing may be up to $275 million.","length":310,"tagName":"p"}]},{"va...